What Happened?
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.
Meacham wrote in a note to clients that the stock's surge since mid-August's Phase 3 INTerpath-001 melanoma readout reflects aggressive sales forecasts and unrealistic probability-of-success assumptions. Reaching a near-$200 share price would require roughly $13 billion in annual oncology revenue attributable to Moderna—nearly seven times Citigroup’s model—a hurdle Meacham characterized as unrealistic. The run-up expanded Moderna’s market capitalization to roughly $80 billion, rivaling Regeneron despite materially lower expected revenue and earnings, according to the note. Meacham added that even under a theoretical 100% probability of success across lead cancer programs, Citigroup's pipeline valuation model justifies only about $100 per share.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Moderna? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Moderna’s shares are extremely volatile and have had 60 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 9 days ago when the stock gained 9.4% on the news that positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.
The advance extended previous gains from the clinical study rather than new company disclosures, reflecting sustained investor optimism following the melanoma trial data per StreetInsider. The stock has also been bolstered by Wall Street upgrades from Argus and Bank of America. Furthermore, regulatory sentiment improved after the Food and Drug Administration approved Moderna's updated 2026-2027 COVID-19 vaccines. These developments follow a $2.6 billion convertible note offering completed in late August to provide dedicated funding for ongoing oncology development.
Moderna is up 520% since the beginning of the year, and at $191.35 per share, it is trading close to its 52-week high of $203.46 from September 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at only $496.97.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.